Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635976 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL19635977 | 0.82 | PDE4B (0.43) | SMN1; SMN2CYP2C19NPC1RAB9AHTR2C | |
| SCHEMBL15669761 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL25498781 | 0.77 | HTR2C (0.47) | SMN1; SMN2CYP2C19NPC1RAB9ATSHR | |
| SCHEMBL15669673 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL26602521 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL16075645 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL15670110 | 0.75 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL15669499 | 0.75 | HTR2C (0.50) | SMN1; SMN2CYP2C19NPC1RAB9ATSHR | |
| SCHEMBL696467 | 0.75 | SMN1; SMN2 (0.69) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708165-B1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SINOMAB BIOSCIENCE LTD (CN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3459940-B1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SUZHOU SINOVENT PHARMACEUTICALS CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | SINOMAB BIOSCIENCE LIMITED (HK) | 2021-11-23 | — | — | US | disclosed |
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SUZHOU SINOVENT PHARMA CO., LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3708165-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | Sinomab Bioscience Limited (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3459940-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Zhejiang Yukon Pharma Co., Ltd. (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198050-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 浙江予川医药科技有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | BTK, SYK, LCK | SMN1; SMN2 4637/4885CYP2C19 235/4885NPC1 4331/4885 |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | BTK, SYK, LCK | SMN1; SMN2 4806/4885CYP2C19 2017/4885NPC1 4532/4885 |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | BTK, SYK, LCK | SMN1; SMN2 4806/4885CYP2C19 2017/4885NPC1 4532/4885 |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | BTK, SYK, LCK | SMN1; SMN2 4637/4885CYP2C19 235/4885NPC1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.